Innes, S;
Harvey, J;
Collins, IJ;
Cotton, MF;
Judd, A;
(2018)
Lipoatrophy/Iipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland.
PLoS ONE
, 13
(4)
10.1371/journal.pone.0194132.
Preview |
Text
Innes et al. LA and LH in CHIPS (Plos One 2018).pdf - Published Version Download (1MB) | Preview |
Abstract
BACKGROUND: Following widespread use of stavudine, a thymidine analogue, in antiretroviral therapy (ART) over the past three decades, up to a third of children developed lipoatrophy (LA) and/or lipohypertrophy (LH). Following phasing-out of stavudine, incidence of newly-diagnosed LA and LH declined dramatically. However, the natural history of existing cases should be explored, particularly with prolonged protease inhibitor exposure. METHODS: The Collaborative HIV Paediatric Study (CHIPS) is a multicentre cohort study of most HIV-infected children in the United Kingdom and Ireland. Those on ART with a LA/LH assessment recorded in 2003–2011 were included. Assessments were completed annually by consultant physicians. Using the 0–3 grading system, LA or LH was defined as grade 2 or 3. Resolution was defined as return to grade 1 or 0 in all body regions. RESULTS: Of 1345 children followed for median (IQR) 5.5 (2.9, 8.2) years after ART initiation, 30 developed LA and 27 developed LH, all at least 2 years after ART initiation. Median age at LA diagnosis was 11 (10, 13) years and at LH diagnosis was 13 (11, 15) years. Children with LA were more likely white (p<0.0001); lower height-for-age z-score at ART initiation (p = 0.02); initiated ART earlier (p = 0.04), with longer ART exposure (p = 0.04). Children with LH were similar to those without. Analysis of individual drugs revealed that LA was associated with greater duration of exposure to stavudine and didanosine; while LH was associated with greater duration of exposure to stavudine and ritonavir (given alone or in combination with another protease inhibitor). Median time in follow-up following ART switch was 2.8 (1.9, 4.9) and 2.5 (1.6, 4.7) years respectively. Resolution occurred in 10 (30%) of LA cases (median time to resolution 2.3 [1.8, 3.6] years) and 3 (11%) of LH cases (median time to resolution 2.0 [1.7, 2.1] years). CONCLUSIONS: Prevalence of LA and LH were low, with some resolution noted, especially for LA. More long-term data are needed.
| Type: | Article |
|---|---|
| Title: | Lipoatrophy/Iipohypertrophy outcomes after antiretroviral therapy switch in children in the UK/Ireland |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1371/journal.pone.0194132 |
| Publisher version: | http://dx.doi.org/10.1371/journal.pone.0194132 |
| Language: | English |
| Additional information: | © 2018 Innes et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| Keywords: | Science & Technology, Multidisciplinary Sciences, Science & Technology - Other Topics, HIV-INFECTED CHILDREN, BODY-FAT CHANGES, RISK-FACTORS, LIPODYSTROPHY, INHIBITOR, STAVUDINE, LIPOATROPHY, PREVALENCE, SUBSTITUTION, ADOLESCENTS |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology > MRC Clinical Trials Unit at UCL |
| URI: | https://discovery-pp.ucl.ac.uk/id/eprint/10047649 |
Archive Staff Only
 |
View Item |
